Chikara Οhyama

12.9k total citations · 1 hit paper
524 papers, 9.3k citations indexed

About

Chikara Οhyama is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Chikara Οhyama has authored 524 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 221 papers in Surgery, 206 papers in Pulmonary and Respiratory Medicine and 122 papers in Molecular Biology. Recurrent topics in Chikara Οhyama's work include Bladder and Urothelial Cancer Treatments (150 papers), Urinary and Genital Oncology Studies (102 papers) and Prostate Cancer Treatment and Research (101 papers). Chikara Οhyama is often cited by papers focused on Bladder and Urothelial Cancer Treatments (150 papers), Urinary and Genital Oncology Studies (102 papers) and Prostate Cancer Treatment and Research (101 papers). Chikara Οhyama collaborates with scholars based in Japan, United States and United Kingdom. Chikara Οhyama's co-authors include Takuya Koie, Yasuhiro Hashimoto, Tohru Yoneyama, Shingo Hatakeyama, Hayato Yamamoto, Takahiro Yoneyama, Shingo Hatakeyama, Yuki Tobisawa, Tomonori Habuchi and Minoru Fukuda and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Chikara Οhyama

494 papers receiving 9.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

2017 1.2k citations Chikara Οhyama et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Chikara Οhyama	3.5k	3.0k	2.6k	2.2k	1.5k	524	9.3k
Hideaki Miyake	4.0k 1.2×	2.7k 0.9×	4.7k 1.8×	3.2k 1.5×	795 0.5×	620	10.8k
Luan D. Truong	4.3k 1.2×	2.3k 0.8×	3.6k 1.4×	1.6k 0.7×	743 0.5×	288	11.9k
Dan Theodorescu	7.5k 2.2×	3.8k 1.3×	3.1k 1.2×	3.6k 1.7×	1.2k 0.8×	335	14.6k
Sam S. Chang	2.2k 0.6×	4.9k 1.6×	3.1k 1.2×	2.4k 1.1×	774 0.5×	209	9.9k
Pierluigi Benedetti Panici	2.8k 0.8×	3.9k 1.3×	1.2k 0.4×	3.6k 1.7×	1.4k 0.9×	566	16.0k
Yoshiyuki Kakehi	2.7k 0.8×	1.9k 0.6×	2.7k 1.0×	1.6k 0.8×	357 0.2×	262	7.0k
Anil Kapoor	4.7k 1.4×	2.1k 0.7×	5.3k 2.1×	2.1k 1.0×	510 0.3×	403	9.9k
Dominique Chopin	4.7k 1.3×	5.0k 1.7×	5.4k 2.1×	1.7k 0.8×	587 0.4×	257	11.6k
Barbara A. Foster	3.6k 1.0×	778 0.3×	2.0k 0.8×	2.0k 0.9×	2.4k 1.7×	138	9.0k
Leonard G. Gomella	3.4k 1.0×	2.6k 0.9×	6.7k 2.6×	2.5k 1.2×	482 0.3×	385	12.7k

Countries citing papers authored by Chikara Οhyama

Since Specialization

Citations

This map shows the geographic impact of Chikara Οhyama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chikara Οhyama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chikara Οhyama more than expected).

Fields of papers citing papers by Chikara Οhyama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chikara Οhyama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chikara Οhyama. The network helps show where Chikara Οhyama may publish in the future.

Co-authorship network of co-authors of Chikara Οhyama

This figure shows the co-authorship network connecting the top 25 collaborators of Chikara Οhyama. A scholar is included among the top collaborators of Chikara Οhyama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chikara Οhyama. Chikara Οhyama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saito, Mitsuru, Shinya Maita, Reiichi Murakami, et al.. (2025). Benefits of Preemptive Living Kidney Transplantation: Reduced Rates of Cerebro‐Cardiovascular Events and Neoplasm Development. International Journal of Urology. 32(12). 1843–1850.

Narita, Takuma, Yuki Tobisawa, Andrey A. Bobkov, et al.. (2023). TMEM2 is a bona fide hyaluronidase possessing intrinsic catalytic activity. Journal of Biological Chemistry. 299(9). 105120–105120. 14 indexed citations

Fujita, Naoki, Masaki Momota, Yuki Tobisawa, et al.. (2023). Can Erectile Dysfunction Severity Predict Major Adverse Cardiovascular Events in Men Undergoing Dialysis? A Prospective Cohort Study. The World Journal of Men s Health. 41(4). 900–900. 1 indexed citations

Fujita, Naoki, Hiroyuki Suganuma, Shingo Hatakeyama, et al.. (2023). Association between Advanced Glycation End-Products, Carotenoids, and Severe Erectile Dysfunction. The World Journal of Men s Health. 41(3). 701–701. 7 indexed citations

Hatakeyama, Shingo, Hideo Kawaguchi, Yoshiomi Hatayama, et al.. (2021). Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study. Urologic Oncology Seminars and Original Investigations. 40(2). 64.e1–64.e8. 11 indexed citations

Hatano, Koji, Tohru Yoneyama, Shingo Hatakeyama, et al.. (2021). Simultaneous analysis of serum α2,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer. British Journal of Cancer. 126(5). 764–770. 17 indexed citations

Irie, Fumitoshi, et al.. (2021). The cell surface hyaluronidase TMEM2 regulates cell adhesion and migration via degradation of hyaluronan at focal adhesion sites. Journal of Biological Chemistry. 296. 100481–100481. 30 indexed citations

Kubota, Yuka, Shingo Hatakeyama, Hayato Yamamoto, et al.. (2020). Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: A multicenter study. European Urology Open Science. 19. e311–e312. 2 indexed citations

Momota, Masaki, Shingo Hatakeyama, Osamu Soma, et al.. (2020). Geriatric 8 screening of frailty in patients with prostate cancer. International Journal of Urology. 27(8). 642–648. 33 indexed citations

10.

Fujita, Naoki, Shingo Hatakeyama, Masaki Momota, et al.. (2020). Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer. Urologic Oncology Seminars and Original Investigations. 38(8). 684.e17–684.e24. 9 indexed citations

11.

Yoneyama, Tohru, Daisuke Noro, Yuki Tobisawa, et al.. (2019). The Impact of Glycosylation of Osteopontin on Urinary Stone Formation. International Journal of Molecular Sciences. 21(1). 93–93. 15 indexed citations

12.

Fujita, Naoki, Takuya Koie, Yasuhiro Hashimoto, et al.. (2018). Neoadjuvant chemohormonal therapy followed by robot-assisted and minimum incision endoscopic radical prostatectomy in patients with high-risk prostate cancer: comparison of perioperative and oncological outcomes at single institution. International Urology and Nephrology. 50(11). 1999–2005. 11 indexed citations

13.

Yamamoto, Hayato, Takuya Koie, Koji Mitsuzuka, et al.. (2018). Can single positive core prostate cancer at biopsy be considered a low-risk disease?. International Urology and Nephrology. 50(10). 1829–1833. 3 indexed citations

14.

Noro, Daisuke, Tohru Yoneyama, Shingo Hatakeyama, et al.. (2017). Serum Aberrant N-Glycan Profile as a Marker Associated with Early Antibody-Mediated Rejection in Patients Receiving a Living Donor Kidney Transplant. International Journal of Molecular Sciences. 18(8). 1731–1731. 10 indexed citations

15.

Tobisawa, Yuki, Takatoshi Kaya, Shingo Hatakeyama, et al.. (2017). Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer. International Journal of Molecular Sciences. 18(2). 261–261. 33 indexed citations

16.

Koie, Takuya, et al.. (2017). Longer recurrence‐free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus. Clinical Case Reports. 5(12). 1950–1953. 2 indexed citations

17.

Yoneyama, Tohru, Yuki Tobisawa, Shingo Hatakeyama, et al.. (2017). An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis. International Journal of Molecular Sciences. 18(2). 470–470. 43 indexed citations

18.

Noguchi, Masanori, Kazumasa Matsumoto, Hirotsugu Uemura, et al.. (2015). An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy. Clinical Cancer Research. 22(1). 54–60. 49 indexed citations

19.

Koie, Takuya, Chikara Οhyama, Hayato Yamamoto, et al.. (2014). Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy. Urologic Oncology Seminars and Original Investigations. 32(6). 820–825. 25 indexed citations

20.

Akama, Tomoya O., Hiroaki Nakagawa, Kazuhiro Sugihara, et al.. (2002). Germ Cell Survival Through Carbohydrate-Mediated Interaction with Sertoli Cells. Science. 295(5552). 124–127. 119 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact